Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CTST NASDAQ:GLYC NASDAQ:HROW NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSTCannTrustC$0.64C$0.64C$0.38▼C$8.17C$90.27MN/AN/AN/AGLYCGlycoMimetics$0.16-6.6%$13.48$14.06▼$63.00$10.00M1.6267,672 shs1.05 million shsHROWHarrow$44.34-2.3%$37.28$20.85▼$59.23$1.68B0.33522,687 shs756,242 shsSVRASavara$3.53-1.9%$3.00$1.89▼$4.70$622.21M0.561.64 million shs3.69 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSTCannTrust0.00%0.00%0.00%0.00%0.00%GLYCGlycoMimetics0.00%0.00%0.00%0.00%-99.05%HROWHarrow-2.29%+12.48%+15.98%+44.62%-2.18%SVRASavara-1.94%-0.84%+14.24%+71.36%-20.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSTCannTrustC$0.64C$0.64C$0.38▼C$8.17C$90.27MN/AN/AN/AGLYCGlycoMimetics$0.16-6.6%$13.48$14.06▼$63.00$10.00M1.6267,672 shs1.05 million shsHROWHarrow$44.34-2.3%$37.28$20.85▼$59.23$1.68B0.33522,687 shs756,242 shsSVRASavara$3.53-1.9%$3.00$1.89▼$4.70$622.21M0.561.64 million shs3.69 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSTCannTrust0.00%0.00%0.00%0.00%0.00%GLYCGlycoMimetics0.00%0.00%0.00%0.00%-99.05%HROWHarrow-2.29%+12.48%+15.98%+44.62%-2.18%SVRASavara-1.94%-0.84%+14.24%+71.36%-20.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSTCannTrust 0.00N/AN/AN/AGLYCGlycoMimetics 3.00BuyN/AN/AHROWHarrow 2.88Moderate Buy$64.6745.84% UpsideSVRASavara 2.83Moderate Buy$7.50112.46% UpsideCurrent Analyst Ratings BreakdownLatest SVRA, GLYC, HROW, and CTST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025HROWHarrowZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/9/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.009/8/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $8.009/3/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.008/15/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $6.008/15/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.00 ➝ $5.008/14/2025HROWHarrowZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/14/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $63.008/13/2025HROWHarrowHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $64.007/11/2025HROWHarrowCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$76.00(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSTCannTrustC$35.22M2.56N/AN/AN/A∞GLYCGlycoMimetics$10K1,000.25N/AN/A$0.08 per share1.94HROWHarrow$199.61M8.22$0.13 per share331.87$1.95 per share22.74SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSTCannTrust-C$10.46MN/A0.00∞N/AN/AN/AN/AN/AGLYCGlycoMimetics-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%N/AHROWHarrow-$17.48M-$0.25N/A110.85N/A-4.49%-2.18%-0.35%11/12/2025 (Estimated)SVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest SVRA, GLYC, HROW, and CTST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/11/2025Q2 2025HROWHarrow$0.01$0.24+$0.23$0.13$64.23 million$63.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTSTCannTrustN/AN/AN/AN/AN/AGLYCGlycoMimeticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSTCannTrustN/AN/AN/AGLYCGlycoMimeticsN/A1.921.92HROWHarrow0.780.620.58SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSTCannTrust0.03%GLYCGlycoMimetics75.19%HROWHarrow72.76%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipCTSTCannTrustN/AGLYCGlycoMimetics8.70%HROWHarrow15.16%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSTCannTrust576141.49 millionN/AOptionableGLYCGlycoMimetics5064.53 million58.90 millionOptionableHROWHarrow18037.00 million31.39 millionOptionableSVRASavara20172.84 million163.63 millionOptionableSVRA, GLYC, HROW, and CTST HeadlinesRecent News About These CompaniesROSEN, A RANKED AND LEADING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– SVRA4 hours ago | globenewswire.comNovember 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SVRASeptember 19 at 4:47 PM | globenewswire.comROSEN, LEADING INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action- SVRASeptember 19 at 3:51 PM | cantechletter.comCDeadline Alert: Savara Inc. (SVRA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitSeptember 19 at 1:09 PM | globenewswire.comShareholders of Savara Inc. Should Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights - SVRASeptember 19 at 10:50 AM | theglobeandmail.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraSeptember 19 at 10:50 AM | cantechletter.comCROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action- SVRASeptember 19 at 10:50 AM | cantechletter.comCInvestors who lost money on Savara Inc.(SVRA) should contact Levi & Korsinsky about pending Class Action - SVRASeptember 19 at 8:45 AM | prnewswire.comFaruqi & Faruqi Reminds Savara Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 - SVRASeptember 18 at 6:13 PM | prnewswire.comSavara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights – SVRASeptember 18 at 4:44 PM | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Savara, Inc. InvestorsSeptember 18 at 1:41 PM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRASeptember 18 at 10:00 AM | prnewswire.comRecover Investment Losses: Levi & Korsinsky Files Class Action Against Savara Inc. (SVRA)September 18 at 4:32 AM | theglobeandmail.comRecover Investment Losses: Levi & Korsinsky Files Class Action Against Savara Inc. (SVRA)September 18 at 4:32 AM | theglobeandmail.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 18 at 4:32 AM | prnewswire.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraSeptember 17 at 10:11 PM | globenewswire.comDeadline Alert: Savara Inc. (SVRA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitSeptember 17 at 1:52 PM | businesswire.comROSEN, A LEADING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – SVRASeptember 17 at 12:29 PM | globenewswire.comDid You Lose Money in SVRA? Shareholders Who Lost Money in SVRA Should Contact Robbins LLP for Information About the Savara Inc. Securities Class Action LawsuitSeptember 16, 2025 | prnewswire.comSVRA Investors have Opportunity to Lead Savara Inc. Securities Fraud LawsuitSeptember 16, 2025 | prnewswire.comSavara (NASDAQ:SVRA) Stock Price Down 3.3% - Should You Sell?September 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSVRA, GLYC, HROW, and CTST Company DescriptionsCannTrust NYSE:CTSTCannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.GlycoMimetics NASDAQ:GLYCGlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Harrow NASDAQ:HROW$44.34 -1.04 (-2.29%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$44.49 +0.15 (+0.34%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Savara NASDAQ:SVRA$3.53 -0.07 (-1.94%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$3.49 -0.04 (-1.13%) As of 09/19/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
